CBS 2019
CBSMD教育中心
中 文

DAPT Duration

Abstract

Recommended Article

Conceptual Framework for Addressing Residual Atherosclerotic Cardiovascular Disease Risk in the Era of Precision Medicine Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial Impact of bleeding during dual antiplatelet therapy in patients with coronary artery disease Patient-tailored antithrombotic therapy following percutaneous coronary intervention Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial Comparison of 1-month Versus 12-month Dual Antiplatelet Therapy after Implantation of Drug-eluting Stents Guided by either Intravascular Ultrasound or Angiography in Patients with Acute Coronary Syndrome: Rationale and Design of Prospective, Multicenter, Randomized, Controlled IVUS-ACS & ULTIMATE-DAPT trial Patient Selection and Clinical Outcomes in the STOPDAPT-2 Trial: An All-Comer Single-Center Registry During the Enrollment Period of the STOPDAPT-2 Randomized Controlled Trial

Guideline2016 Nov;152(5):1243-1275.

JOURNAL:J Thorac Cardiovasc Surg. Article Link

2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

Levine GN, Bates ER, Bittl JA et al. Keywords: AHA; P2Y(12) inhibitor; Scientific Statements; acute coronary syndrome; aspirin; coronary artery disease; coronary stents; dual antiplatelet therapy (DAPT); focused update; stable ischemic heart disease

FULL TEXT PDF